← All trials
NCT05036005
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Jan 31, 2023
- First posted
- Sep 5, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 108
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institut fuer FrauengesundheitLead sponsor
- SamsungCollaborator
- Humboldt UniversityStudy chair
- University of HeidelbergStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.